Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $170 to $195.
Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $170 to $195.